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Aims To identify population, general practitioner, and practice characteristics associated with the achievement of
HbA1c, blood pressure and LDL cholesterol targets, and to describe variation in the achievement of risk factor control.
Methods We conducted a cross-sectional survey of 9342 people with type 2 diabetes, 281 general practitioners and 77
general practices in Norway. Missing values (7.4%) were imputed using multiple imputation by chained equations. We
used three-level logistic regression with the achievement of HbA1c, blood pressure and LDL cholesterol targets as
dependent variables, and factors related to population, general practitioners, and practices as independent variables.
Results Treatment targets were achieved for HbA1c in 64%, blood pressure in 50%, and LDL cholesterol in 52% of
people with type 2 diabetes, and 17% met all three targets. There was substantial heterogeneity in target achievement
among general practitioners and among practices; the estimated proportion of a GPs diabetes population at target was
55–73% (10–90 percentiles) for HbA1c, 36–63% for blood pressure, and 47–57% for LDL cholesterol targets. The
models explained 11%, 5% and 14%, respectively, of the total variation in the achievement of HbA1c, blood pressure
and LDL cholesterol targets. Use among general practitioners of a structured diabetes form was associated with 23%
higher odds of achieving the HbA1c target (odds ratio 1.23, 95% confidence interval (CI) 1.02–1.47) and 17% higher
odds of achieving the LDL cholesterol target (odds ratio 1.17, 95% CI 1.01–1.35).
Conclusions Clinical diabetes management is difficult, and few people meet all three risk factor control targets. The
proportion of people reaching target varied among general practitioners and practices. Several population, general
practitioner and practice characteristics only explained a small part of the total variation. The use of a structured
diabetes form is recommended.
Diabet. Med. 00, 1–11 (2019)
Introduction
People with type 2 diabetes have a doubled risk of death and
cardiovascular disease compared with the general population
[1]. The risk increases with each risk factor above target [2]. A
meta-analysis of randomized controlled trials (RCTs) has
shown a linear relationship between the reduction in HbA1c
andmajor cardiovascular events [3]. Another meta-analysis of
RCTs, showed that reaching blood pressure targets was
associated with decreased risk of diabetes-related mortality
[4]. Additionally, very low LDL cholesterol level was associ-
ated with reduced cardiovascular risk in people with type 2
diabetes [5]. It is therefore important for people with diabetes
to achieveHbA1c, blood pressure and LDL cholesterol targets.
Healthcare services in Norway are state-funded. Each
member of the population is listed with one specific general
practitioner (GP). GPs provide care for most individuals with
type 2 diabetes; however, they do not receive financial
incentives for the provision of a high quality of clinical care.
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In a recent study, we found major gaps between national
diabetes guidelines and the performance of screening to
detect microvascular complications, with significant hetero-
geneity among GPs within general practices [6]. The aim of
the present study was to examine how population charac-
teristics and available GP and practice characteristics were
associated with the achievement of HbA1c, blood pressure
and LDL cholesterol targets. In addition, we describe
variation in the achievement of targets.
Participants and methods
We used data from the ROSA 4 study, a cross-sectional
survey designed to assess the quality of diabetes care in
general practice in Norway in 2014. Verified and represen-
tative data from electronic health records in three of the four
health regions in Norway were collected and are described in
detail elsewhere [6].
In the present study we included 9342 adults (age ≥18
years) with type 2 diabetes (T90 in the International
Classification of Primary Care) who had their main follow-
up in their general practice, and who had a diabetes duration
of ≥6 months (Fig. 1). The included population was treated
by 281 GPs at 77 practices (73% and 77%, respectively, of
those invited to contribute data). Socio-economic variables
were obtained from Statistics Norway. Two questionnaires
were used to gather GP and practice characteristics (com-
pleted in 99% and 100% of cases).
The outcome variables were defined according to national
guidelines from 2009: HbA1c ≤53 mmol/mol (≤7.0%), blood
pressure ≤135/80 mmHg/≤140/85 mmHg (with/without anti-
hypertensive medication) and LDL cholesterol ≤1.8 mmol/l
with cardiovascular disease, or ≤2.5/≤3.5 mmol/l without
cardiovascular disease with/without lipid-lowering medica-
tion. We used the most recent target value between 1
October 2013 and 31 December 2014, although, if none was
available, the search period was extended backwards to 1
January 2012 (7.8% of HbA1c measurements and 19.1% of
LDL cholesterol measurements).
As explanatory variables, we included 12 diabetes popu-
lation characteristics (demographics, socio-economic status,
complications), 10 GP characteristics (demographics, spe-
ciality status and proxies for workload and routines), and
four practice characteristics (location, proxies for practice
size and routines); Table 1a,b.
Statistical analyses
Descriptive statistics are presented as medians with 10th and
90th percentiles for continuous variables, and counts and
percentages for categorical variables. Missing information
regarding individuals with diabetes (7.4%) was imputed
using multiple imputation by chained equations with predic-
tive mean matching, allowing for the multilevel structure of
the data [7]. In addition to the variables in the main models,
the imputations included the following as auxiliary variables:
weight; height; HbA1c; systolic blood pressure; diastolic
blood pressure; total cholesterol; HDL cholesterol; LDL
cholesterol; triglycerides; retinopathy; atrial fibrillation;
dialysis; and kidney transplantation. We produced 100
imputed datasets. Furthermore, number of years practising
in Norway was unknown for 11 GPs, and was single-
imputed based on the year of Norwegian authorization,
which was known for all GPs.
The associations between the outcomes and population,
GP and practice characteristics were analysed in three-level
logistic regression models including random intercepts for
GPs (level 2) and practices (level 3). Continuous explanatory
variables with severely non-linear effects on the log-odds
were analysed on a categorized scale. Variance inflation
factors were estimated to check for multicollinearity. We
report odds ratios (ORs) with 95% CIs for the achievement
of targets. Because of the large sample size and multiple
testing, corresponding chi-squared P values ≤0.01 for pop-
ulation characteristics and ≤0.05 for GP and practice
characteristics were considered statistically significant. The
models were fitted using adaptive Gaussian quadrature with
seven integration points. Results from the imputed datasets
were averaged by Rubin’s rules.
The proportion of variance explained by each full model
was estimated from the variance of the linear predictor for
the fixed portion of the model and from the estimated
random intercepts variances [8].
Heterogeneity in the achievement of targets among GPs
within practices was illustrated by means of ‘caterpillar’ plots
of empirical Bayes estimates of target achievement propor-
tions, obtained from three-level models without fixed effects
What’s new?
• Only one in five of those with type 2 diabetes in primary
care in Norway met all three targets for HbA1c, blood
pressure and LDL cholesterol.
• There was substantial heterogeneity in the achievement
of HbA1c, blood pressure and LDL cholesterol targets
among general practitioners and practices.
• The heterogeneity in risk factor control remained after
adjustment for case mix.
• Detailed analysis with 12 population-related, 10 gen-
eral practitioner-related and four practice-related fac-
tors explained <15% of the total variation in target
achievement.
• Most of the variation was at the population level.
• Young people, obese people and those with macrovas-
cular complications achieved targets less frequently.
• The use of a structured diabetes form is recommended.
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fitted to the original data, and with percentiles from the
empirical Bayes distributions. The total variation in the plots
reflects the sum of GP and practice random effects.
Furthermore, median ORs were calculated from the
estimated random intercept variances to quantify the cluster
heterogeneity [9], and are presented for GPs, practices, and
GPs and practices combined.
Finally, intraclass correlation coefficients were used to
estimate the proportion of outcome or residual variation
attributed to GPs, practices, and GPs within practices. The
CIs of intraclass correlation coefficients were estimated using
the logit transform as described in the STATA documentation
of estat icc, with standard errors estimated by the delta
method [10].
Supplementary analyses included linear regression analysis
with continuous outcomes and complete-case analysis.
The Venn diagram was made in PYTHON version 3.7 with
package matplotlib. Imputation was performed in R version
3.4 with packages mice and miceadds. For the regression
modelling, STATA version 15.1 was used with functions mi
estimate, melogit, mixed, and mimrgns.
Ethics
The study was approved by the Regional Health Commitee
in Norway (REK 2014/1374, REK Vest).
Results
The included population (n=9342; Fig. 1) was treated by 281
GPs at 77 practices (Table 1a,b). For the diabetes population
in which HbA1c, blood pressure and LDL cholesterol values
were available for all (n=7086), 64% achieved the HbA1c
target, 50% the blood pressure target and 52% the LDL
cholesterol target, and 17%met all three targets (Fig. 2). The
median (10th–90th percentile) values were as follows: HbA1c
51 (40–68) mmol/mol [6.8 (5.8–8.4%)]; systolic blood
pressure 134 (116–156) mmHg; diastolic blood pressure 80
(66–90) mmHg; and LDL cholesterol 2.6 (1.6–4.0).
Tables 2a and 2b show the estimated associations between
the achievement of targets and population, GP and practice
characteristics.
HbA1c
Compared with people in the age group 60–69 years, those
aged<50 yearswere less likely to achieve theHbA1c target (OR
0.60, 95% CI 0.51–0.71), while those aged ≥70 years were
more likely to achieve the target (Table 2a).Men, people born
outside Western Europe, and people with obesity had lower
odds of attaining the target. Long diabetes duration was also
negatively associated with the achievement of HbA1c target
(OR 0.65, 95%CI 0.62–0.67) per 5-year increase. People who
had undergone bariatric surgery had almost three times higher
odds of attaining the HbA1c target (OR 2.78, 95% CI 1.82–
4.25). People attending GPs who were regular users of a
structured diabetes form had 23%higher odds of attaining the
HbA1c target, (OR 1.23, 95% CI 1.02–1.47; Table 2b).
Blood pressure
People aged < 50 years were more likely to achieve blood
pressure targets (OR 1.49, 95% CI 1.26–1.77). Non-Western
ethnicity was positively associated with the achievement of
the blood pressure target, in particular South Asian ethnicity
(OR 1.99, 95% CI 1.61–2.46). Current smokers had higher
odds of achieving the blood pressure target (OR 1.20, 95%
CI 1.05–1.38). Obese people had reduced odds of achieving
the target (OR 0.76, 95% CI 0.66–0.87), while those with
BMI < 25 kg/m2 had increased odds of attaining blood
FIGURE 1 Flow chart of the exclusion process of participants in the ROSA 4 study (Rogaland-Oslo-Salten-Akershus-Hordaland study in 2014). GP,
general practitioner; LADA, latent autoimmune diabetes in adults; MODY, maturity-onset diabetes of the young.
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pressure target compared with those with BMI 25–29.9 kg/
m2 (OR 1.40, 95% CI 1.17–1.68). No GP or practice
characteristics were associated with the achievement of the
blood pressure target in our model.
LDL cholesterol
Men had higher odds of achieving the LDL cholesterol target
compared with women (OR 1.51, 95% CI 1.36–1.67). A
positive association with the achievement of LDL cholesterol
target was found in people of other ethnicity compared with
those of Western European/North American and South Asian
ethnicity (OR 1.39, 95% CI 1.16–1.66) and ex-smokers (OR
1.24, 95% CI 1.09–1.40). For each 5-year increase in
diabetes duration, the odds of reaching the LDL cholesterol
target increased by 18% (OR 1.18, 95% CI 1.13–1.23).
People with macrovascular complications were less likely to
achieve the LDL cholesterol target (OR 0.20, 95% CI 0.18–
0.22). GP users of a structured diabetes form had 17% higher
odds of getting the individuals with diabetes to the LDL
cholesterol target (OR 1.17, 95% CI 1.01–1.35).
Supplementary analyses
In supplementary analyses, models with continuous out-
comes mostly paralleled results from the logistic regression
Table 1a Characteristics of 9342 people with type 2 diabetes included
in the study
Missing
observations
n (%)
Observed
median
(10th–90th
percentiles) or
count (%)
Men - 5110 (55)
Age - 66 (48–82)
< 50 years 1194 (13)
50–59 years 1884 (20)
60–69 years 2766 (30)
70–79 years 2231 (24)
≥ 80 years 1267 (14)
Ethnicity 7 (0.1)
Western European/
North American*
7766 (83)
South Asian† 726 (7.8)
Other 843 (9.0)
Education 181 (1.9)
Primary school - 3373 (37)
High school/apprenticeship - 4102 (45)
University - 1686 (18)
Diabetes duration (years) 562 (6.0) 7 (1-18)
Smoking status 1933 (21)
Never smoked 3315 (45)
Ex-smoker 2413 (33)
Current smoker 1681 (23)
BMI 5153 (55) 29 (24-38)
< 25 kg/m2 772 (18)
25–29.9 kg/m2 1558 (37)
≥ 30 kg/m2 1859 (44)
Bariatric surgery 12 (0.1) 143 (1.5)
Macrovascular complications‡ 22 (0.2) 2513 (27)
Foot ulcer 13 (0.1) 251 (2.7)
Lower limb amputation 8 (0.1) 55 (0.6)
Estimated GFR 452 (4.8)
> 60 ml/min/1.73 m2 7489 (84)
45–59 ml/min/1.73 m2 839 (9.4)
30–44 ml/min/1.73 m2 400 (4.5)
< 30 ml/min/1.73 m2 162 (1.8)
*Born in Western Europe or North America. †Born in
Bangladesh, India, Pakistan or Sri-Lanka. ‡Composite variable
of either coronary heart disease, stroke and/or peripheral
arterial surgery.
Table 1b Characteristics of 281 general practitioners and 77 practices
included in the study
Missing
observations,
n (%)
Observed
median
(10th–90th
percentiles)
or count (%)
GPs (n = 281)
Men - 155 (55)
Age - 50 (34–64)
< 40 years 65 (23)
40–49 years 75 (27)
50–59 years 65 (23)
≥ 60 years 76 (27)
Born outside Norway - 53 (19)
Medical education
outside Norway
- 82 (29)
Years as a GP in Norway 11 (3.9) 18 (3–35)
≤ 5 years as a
GP in Norway
49 (18)/(20)*
Specialist in general practice - 189 (67)
Number of people with type
2 diabetes on list
- 34 (14–60)
< 25 66 (24)
25–49 132 (47)
≥ 50 83 (30)
Clinical days per week > 3 - 229 (82)
Total number of people
on GP’s list per day
worked each week
- 296 (218–392)
< 225 73 (26)
225–300 81 (29)
301–375 94 (34)
> 375 33 (12)
User of a structured
diabetes form†
- 73 (26)
Practice (n = 77)
County
Oslo - 12 (16)
Akershus - 10 (13)
Hordaland - 10 (13)
Rogaland - 19 (25)
Nordland - 26 (34)
Number of GPs per office - 3 (1-6)
Number of people on list
per full-time ancillary staff
- 1427 (805–1989)
< 1250 24 (31)
1250–1750 35 (46)
> 1750 18 (23)
Routines of annual diabetes
review/reminders
- 19 (25)
GP, general practitioner.
*Percentage after imputation. †GP defined as a user of the form
if used in ≥10 people with diabetes or more than 50% of the
people with diabetes on the GP’s list.
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analysis (Table S1). Predicted probabilities are presented in
Table S2. In the complete-case analyses (n=3530 for HbA1c
target, n=3462 for blood pressure target, n=3308 for LDL
cholesterol target; data not shown), there were only minor
changes in the effect estimates, that is, the effect of using a
diabetes form was slightly reduced, in particular for achiev-
ing the LDL cholesterol target which was non-significant. In
analyses excluding people aged ≥80 years, the results were
similar to the full model (data not shown).
Variation
The fixed effects of the full model explained 11% of the
variation in achievement of HbA1c target, whereas fixed and
random effects together explained 16% of the variation. The
corresponding results for the blood pressure target were 5%
and 11%, and for LDL cholesterol target 14% and 16%.
We found statistically significant variation among GPs and
among practices for all targets. Figures 3a–c show the varia-
tion in predicted proportions of target achievement for the
individual GPs within practices. For the HbA1c target, 80% of
GPs within practices were predicted to lie between 55% and
73% target achievement. For blood pressure target the
variation was bigger, with the 10th to 90th percentile predicted
target achievement range being 36% to63%;whereas for LDL
cholesterol the corresponding range was 47% to 57%.
Similarly, individuals treated by a well-performing GP
within a well-performing practice had a median 50% higher
odds of HbA1c target achievement than those treated by a GP
with poorer performance at a practice with poorer results
(median OR 1.50, 95% CI 1.36–1.73). For blood pressure
and LDL cholesterol targets the corresponding median ORs
were 1.61 (95% CI 1.45–1.85) and 1.28 (95% CI 1.19–
1.53), respectively. Apart from for LDL cholesterol, the
heterogeneity was distributed relatively evenly between GPs
and practices, and changed only slightly when adjusting for
population, GP and practice factors (Table S3).
By contrast, the residual variation in target achievement
was mostly between individuals. The unconditional com-
bined intraclass correlation coefficients for GPs within
practices were 5.3 (95% CI 3.7–7.5)%, 7.0 (95% CI 5.2–
9.6)% and 2.3 (95% CI 1.4–3.8)% for the HbA1c, blood
pressure and LDL cholesterol targets, respectively, and the
conditional intraclass correlation coefficients from adjusted
models were similar.
Discussion
Clinical management of diabetes is difficult, and only one in
five achieved all three targets for HbA1c, blood pressure and
LDL cholesterol. This is one of few studies with several
explanatory variables on three levels that aim to explore
variation in, and factors associated with, the achievement of
targets [11]. Young people (age <50 years), people with
obesity and those with long diabetes duration were less likely
to achieve the HbA1c target, while people with macrovascu-
lar disease had lower odds of achieving the LDL cholesterol
target. We observed that a small positive effect on the
achievement of HbA1c and LDL cholesterol targets was
related to GP usage of a structured diabetes form. After
adjusting for case mix, there was a moderate residual
heterogeneity in target achievement among GPs within
FIGURE 2 Proportion of people with type 2 diabetes achieving HbA1c, blood pressure and LDL cholesterol targets where measurements were
available for all (n=7086). HbA1c target: ≤53 mmol/mol (≤7.0%); blood pressure target: ≤135/80 mmHg/≤140/85 mmHg (with/without anti-
hypertensive medication); LDL cholesterol target: ≤1.8 mmol/l with cardiovascular disease, or without cardiovascular disease, ≤2.5/≤3.5 mmol/l
with/without lipid-lowering medication.
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practices, which could only partly be explained by the
studied GP and practice characteristics.
We observed that younger people had worse glycaemic
control than people aged >60 years. This finding has also
been reported in other countries [12,13]. A large observa-
tional study in Sweden showed that people with type 2
diabetes aged <55 years had the highest increase in risk of
cardiovascular disease and death compared with similarly
aged controls [2]. HbA1c level outside target range was also a
strong predictor for all cardiovascular outcomes [2].
People with macrovascular complications had low odds of
attaining the LDL cholesterol target. In the randomized
IMPROVE-IT trial, very low LDL cholesterol levels in people
with type 2 diabetes and acute coronary syndrome reduced
the incidence of cardiovascular outcomes after 7 years
follow-up [5]. Thus, intensification of lipid-lowering therapy
among individuals with a history of macrovascular disease
should be prioritized.
In the present study, obese people were less likely to achieve
HbA1c and blood pressure targets. In the ADDITION-Cam-
bridge trial, weight loss in the first year following a diabetes
diagnosis was associated with reduced incidence of cardio-
vascular disease [14]. Initial weight loss in people with newly
diagnosed type 2 diabetes should therefore be encouraged.
We did not measure adherence to medical or lifestyle
advice, motivation for lifestyle changes, individual prefer-
ences or hypoglycaemic episodes. Poor medication adherence
has been identified as a major cause for the observed efficacy
gap in HbA1c reduction between RCTs and the real world
[15]. A Danish study showed that low frequency of self-
monitoring of blood glucose, perceived low treatment
efficacy, low adherence, and low primary care utilization
were associated with high levels of HbA1c and LDL choles-
terol [16]. In the multinational IntroDia study approximately
one in five people with type 2 diabetes negotiated with their
physician to delay additional medication after initial
Table 2a Characteristics of people with type 2 diabetes with adjusted* odds ratios for the achievement of HbA1c, blood pressure or LDL cholesterol target
Characteristics
HbA1c target
† Blood pressure target‡ LDL cholesterol target§
OR (95% CI) P OR (95% CI) P OR (95% CI) P
N = 9342
Men 0.87 (0.79, 0.96) 0.005 0.96 (0.87, 1.06) 0.43 1.51 (1.36, 1.67) <0.001
Age
< 50 years 0.60 (0.51, 0.71) <0.001 1.49 (1.26, 1.77) <0.001 1.11 (0.94, 1.31) 0.23
50–59 years 0.72 (0.63, 0.82) <0.001 1.15 (1.01, 1.32) 0.038 0.95 (0.83, 1.09) 0.47
60–69 years 1 1 1
70–79 years 1.36 (1.19, 1.56) <0.001 0.84 (0.74, 0.96) 0.009 1.18 (1.03, 1.34) 0.015
≥ 80 years 1.26 (1.06, 1.51) 0.010 0.69 (0.58, 0.82) <0.001 1.21 (1.01, 1.45) 0.04
Ethnicity
Western European/North American¶ 1 1 1
South Asian** 0.66 (0.54, 0.80) <0.001 1.99 (1.61, 2.46) <0.001 1.28 (1.04, 1.56) 0.019
Other 0.67 (0.56, 0.79) <0.001 1.48 (1.24, 1.78) <0.001 1.39 (1.16, 1.66) <0.001
Education
Primary school 1 1 1
High school/apprenticeship 1.06 (0.95, 1.18) 0.30 1.07 (0.96, 1.19) 0.20 1.06 (0.95, 1.18) 0.28
University 1.02 (0.89, 1.17) 0.79 1.02 (0.89, 1.18) 0.74 1.01 (0.88, 1.17) 0.85
Diabetes duration per 5 years 0.65 (0.62, 0.67) <0.001 1.00 (0.97, 1.04) 0.85 1.18 (1.13, 1.23) <0.001
Smoking status
Never smoked 1 1 1
Ex-smoker 1.07 (0.95, 1.21) 0.29 1.10 (0.98, 1.24) 0.12 1.24 (1.09, 1.40) 0.001
Current smoker 0.90 (0.79, 1.04) 0.15 1.20 (1.05, 1.38) 0.009 1.00 (0.86, 1.15) 0.96
BMI
< 25 kg/m2 1.20 (1.00, 1.45) 0.056 1.40 (1.17, 1.68) <0.001 1.08 (0.82, 1.43) 0.58
25–29.9 kg/m2 1 1 1
≥ 30 kg/m2 0.78 (0.67, 0.91) 0.002 0.76 (0.66, 0.87) <0.001 0.94 (0.76, 1.17) 0.57
Bariatric surgery 2.78 (1.82, 4.25) <0.001 1.36 (0.92, 2.00) 0.13 1.61 (1.08, 2.38) 0.018
Macrovascular complications†† 0.92 (0.82, 1.03) 0.15 1.11 (0.99, 1.24) 0.075 0.20 (0.18, 0.22) <0.001
Foot ulcer 0.80 (0.59, 1.09) 0.16 0.74 (0.54, 1.03) 0.071 1.07 (0.76, 1.50) 0.71
Lower limb amputation 0.58 (0.30, 1.15) 0.12 1.34 (0.67, 2.70) 0.41 0.96 (0.47, 1.95) 0.90
Estimated GFR
> 60 ml/min/1.73 m2 1 1 1
45–59 ml/min/1.73 m2 0.95 (0.80, 1.14) 0.59 0.92 (0.78, 1.09) 0.35 1.08 (0.90, 1.28) 0.40
30–44 ml/min/1.73 m2 0.78 (0.61, 0.98) 0.04 1.05 (0.83, 1.33) 0.66 0.87 (0.68, 1.12) 0.29
<30 ml/min/1.73 m2 0.86 (0.60, 1.24) 0.43 0.99 (0.69, 1.41) 0.94 1.13 (0.76, 1.67) 0.55
GP, general practitioner.
*Adjusted for all population, GP and practice characteristics included in Tables 2a and 2b. †HbA1c ≤53 mmol/mol (≤7.0%).
‡Blood pressure
≤135/80 mmHg/≤140/85 mmHg (with/without antihypertensive medication). §LDL cholesterol ≤1.8 mmol/l with cardiovascular disease, or
without cardiovascular disease; ≤2.5/≤3.5mmol/l with/without lipid-lowering medication. ¶Born inWestern Europe or North America. **Born
in Bangladesh, India, Pakistan or Sri-Lanka. ††Composite variable of either coronary heart disease, stroke and/or peripheral arterial surgery.
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monotherapy, two-thirds successfully [17]. A justifiable
source of variation is individualized targets due to multi-
morbidity and short life expectancy, individual preferences
and resources. Personalized treatment leads to a higher
achievement of risk factor control [18] and is encouraged in
international guidelines [19].
People whose GPs used a structured diabetes form were
more likely to achieve the HbA1c and LDL cholesterol targets.
GP usage of the form was also associated with higher odds of
performingmicrovascular screening procedures (OR2.65) [6].
Prescribing and intensifying medication is the GP’s main
tool to influence risk factor control. Due to the cross-
sectional design of the present study, we were not able to
assess GP prescription patterns. GPs’ choices regarding
prescriptions are best studied with longitudinal data. A
review of GPs’ views on barriers to prescribing insulin found
that time constraints, insulin skills, collaboration between
primary and secondary care and perception of barriers for
the person with diabetes influenced the initiation of insulin
[20]. Another review found that delays in initiating or
intensifying anti-hyperglycaemic therapy often exceeded 3
years [21]. Clinical inertia can be related to individuals with
diabetes, their provider and healthcare system [22].
None of the included practice characteristics were signif-
icantly associated with the achievement of targets in the
present study; however, with wide CIs we cannot exclude the
possibility of some effects. A meta-analysis of RCTs showed
no change in HbA1c where nurse prescribers supplemented a
Table 2b Characteristics of general practitioners and practices with adjusted* odds ratios for the achievement of HbA1c, blood pressure or LDL
cholesterol targets
Characteristics
HbA1c target
† Blood pressure target‡ LDL cholesterol target§
OR (95% CI) P OR (95% CI) P OR (95% CI) P
GP (N=281)
Men 1.02 (0.88, 1.19) 0.78 0.91 (0.77, 1.07) 0.23 0.98 (0.85, 1.12) 0.73
Age
< 40 years 1 1 1
40–49 years 1.19 (0.93, 1.51) 0.16 1.15 (0.89, 1.48) 0.29 1.05 (0.86, 1.29) 0.61
50–59 years 0.96 (0.73, 1.25) 0.74 1.18 (0.89, 1.56) 0.24 1.13 (0.90, 1.42) 0.28
≥ 60 years 1.03 (0.79, 1.35) 0.81 0.98 (0.74, 1.30) 0.89 1.04 (0.83, 1.31) 0.72
Born outside Norway 1.08 (0.85, 1.36) 0.53 1.03 (0.80, 1.31) 0.84 0.96 (0.79, 1.17) 0.69
Medical education outside Norway 0.96 (0.79, 1.16) 0.64 1.05 (0.85, 1.28) 0.67 0.96 (0.81, 1.13) 0.64
≤ 5 years as a GP in Norway¶ 1.11 (0.85, 1.45) 0.45 1.05 (0.79, 1.39) 0.76 0.87 (0.69, 1.09) 0.22
Specialist in general practice 1.15 (0.94, 1.41) 0.16 1.04 (0.84, 1.29) 0.70 0.91 (0.77, 1.08) 0.30
Clinical days per week > 3 0.95 (0.76, 1.20) 0.69 0.98 (0.77, 1.24) 0.85 1.06 (0.87, 1.29) 0.57
Number of people with type
2 diabetes per GP
< 25 1 1 1
25–49 1.01 (0.79, 1.28) 0.96 1.14 (0.89, 1.46) 0.30 1.08 (0.88, 1.33) 0.47
≥ 50 0.92 (0.70, 1.22) 0.57 1.16 (0.87, 1.55) 0.32 1.04 (0.82, 1.32) 0.73
Total no. of persons on
GPs list per day worked each week
< 225 1.13 (0.90, 1.42) 0.30 0.89 (0.70, 1.12) 0.32 1.10 (0.92, 1.32) 0.29
225–300 1 1 1
301–375 0.94 (0.79, 1.12) 0.51 0.94 (0.78, 1.13) 0.53 1.02 (0.88, 1.19) 0.77
> 375 1.10 (0.84, 1.43) 0.50 0.82 (0.62, 1.09) 0.17 0.94 (0.75, 1.18) 0.57
User of a structured diabetes form** 1.23 (1.02, 1.47) 0.03 1.09 (0.90, 1.32) 0.40 1.17 (1.01, 1.35) 0.03
Practice (N=77)
County
Oslo 1 1 1
Akershus 1.08 (0.75, 1.56) 0.68 1.10 (0.76, 1.59) 0.62 0.97 (0.77, 1.22) 0.79
Hordaland 1.09 (0.76, 1.56) 0.65 0.93 (0.64, 1.34) 0.69 0.78 (0.62, 0.98) 0.03
Nordland 0.87 (0.61, 1.23) 0.43 0.71 (0.50, 1.01) 0.054 0.75 (0.60, 0.94) 0.013
Rogaland 1.02 (0.74, 1.41) 0.92 1.05 (0.75, 1.46) 0.77 0.78 (0.63, 0.97) 0.02
Number of GPs per office 1.02 (0.96, 1.08) 0.55 0.97 (0.91, 1.03) 0.29 1.01 (0.97, 1.05) 0.59
Number of people on list per
full-time ancillary staff††
< 1250 1 1 1
1250–1750 1.18 (0.86, 1.62) 0.30 0.79 (0.57, 1.09) 0.16 0.90 (0.74, 1.10) 0.31
> 1750 1.09 (0.74, 1.62) 0.66 0.80 (0.54, 1.20) 0.29 0.95 (0.74, 1.21) 0.67
Routines of annual follow-up/reminders 0.97 (0.76, 1.22) 0.78 0.95 (0.75, 1.20) 0.66 1.07 (0.93, 1.24) 0.33
GP, general practitioner.
*Adjusted forall population,GPandpractice characteristics included inTables2aand2b. †HbA1c≤53mmol/mol (≤7.0%).
‡Bloodpressure≤135/
80 mmHg/≤140/85 mmHg (with/without antihypertensive medication). §LDL cholesterol ≤1.8 mmol/l with cardiovascular disease, or without
cardiovascular disease;≤2.5/≤3.5mmol/lwith/without lipid-loweringmedication. ¶Imputed for 11GPs. **GPdefined as auser of the form if used
in ≥10 people with diabetes or more than 50% of the people with diabetes on the GP’s list. ††Ancillary staff: nurses and medical secretaries.
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 7
Research article DIABETICMedicine
(a)
(b)
(c)
8
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
DIABETICMedicine Risk factor control in type 2 diabetes and associated characteristics  A. Bakke et al.
team, however, in people served by nurse prescribers
glycaemic control was non-inferior to people served by GPs
[23]. In other studies significant and positive associations
with diabetes specialized nurses, diabetes team, group
education and reduced HbA1c have been reported [24,25].
Unfortunately, diabetes specialized nurses are rare in Nor-
wegian general practice. Other studies have shown that
multifaceted interventions on multidisciplinary teams
resulted in better glycaemic control [26], and benchmarking
in the multinational OPTIMISE study increased the number
of people achieving blood pressure and LDL cholesterol
targets [27].
We describe statistically significant variation in the pro-
portion of people achieving targets among GPs within
practices, and correspondingly, moderately sized median
ORs and intraclass correlation coefficients. An intraclass
correlation coefficient of 3% for clustering at practices was
found for the combined achievement of HbA1c, blood
pressure and cholesterol in a large study from general
practice in UK [28]. Three-level studies on treatment targets
in general practice are rare; however, one study showed that
> 95% of the variance in HbA1c outcomes was at the
population level, whereas only 2.8% and 1.9% was at the
GP and practice level [11]. The variance pattern did not
change when five population and three GP characteristics
were added to the model. Their model explained 12% of the
total variation; it was very similar to the presented full model
for HbA1c which explained 11% of the variation in our data.
In two-level studies, GP or practice variables explained only
4.9%, 5.7% and 2.1% of the total variation in the
achievement of HbA1c, blood pressure and cholesterol
targets [29,30].
The main strength of the present study was its large sample
of people with diabetes, and inclusion of a substantial
number of GPs within a variety of practice types. This
enabled us to describe variation in outcomes at three levels.
People with diabetes are registered with one specific GP
within one practice and we have assessed several important
variables that are not routinely collected and available in
other studies. The participants are considered to be repre-
sentative of the diabetes population in Norway.
Nevertheless, owing to the cross-sectional design, we were
unable to draw conclusions regarding causality. Further-
more, analyses are based on a single measurement of each
outcome, which may not be representative of the ‘true’ level
of a person’s HbA1c, blood pressure, or LDL cholesterol.
This is mostly a concern with regard to HbA1c and for
shorter disease durations, in which there can be substantial
fluctuations.
The included variables explain only a small part of the
total variation; however, a large proportion of unexplained
variation has also been found in several other prediction
models [11,29,30]. We lack information on population
characteristics regarding diet, physical activity, individual
barriers, adherence to therapy, and comorbidities. We would
also have liked to assess the effect of good GP communica-
tors and dedicated prescribers, GPs with a special interest in
diabetes, and GPs’ barriers to treatment.
The use of electronic health records as a data source can
result in a considerable amount of missing data; however, in
the present study all 9342 medical journals were manually
scrutinized by research nurses who supplemented the
database with information not captured electronically.
Missing data were imputed, including missing measurements
for HbA1c, blood pressure and LDL cholesterol values, which
may protect against bias from data missing not at random
[7].
In summary, the clinical management of diabetes is
challenging, and only one in five people with diabetes
met all three targets for HbA1c, blood pressure and LDL
cholesterol. The largest variation in the achievement of
targets was at the population level. However, the proportion
of people reaching target varied among GPs and practices,
also after adjusting for case mix. Most of the variation in risk
factor control was not explained by the 12 population, 10 GP
and four practice characteristics included in the present
study. Despite this unexplained variation, the clinical impli-
cations of the study are that more attention should be
focused on young people, people with obesity and those with
macrovascular disease, and the use of a structured diabetes
form is recommended.
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